American College of Cardiology Meeting In Brief: Roche's mibefradil

Executive Summary

Roche's mibefradil: In the dose-ranging Mibefradil Ischemia Suppression Trial (MIST) in patients with coronary artery disease and angina, mibefradil significantly increased the time to onset of angina in exercising patients, Dan Tzivoni, MD, Shaare Zedek Medical Center, Jerusalem, reported March 26. Mibefradil additionally increased exercise duration by 11%-24% at different doses, reduced the number of ischemic episodes by 65%-74%, reduced the duration of ischemia by 64%-75% and reduced maximum ST depressions by 50%-62%. Mibefradil is in Phase III in the U.S...